Toward the Definition of New Endpoints
Despite considerable advances in the different treatment modalities, there is no evidence-based consensus in the therapeutic management of diffuse low-grade glioma (DLGG). The typically long overall survival of patients with DLGG makes the usual methodology in oncology of randomized trials inadequate. Moreover, any evaluation of treatment efficacy on overall survival has to be associated with an analysis of functional status in these young patients, who are often not that much affected in the initial phase of their disease. In a first step, we propose a new method to compare the efficacy of the different strategies (advocated in different centers): plotting the time to malignant progression versus the time with quality of life. In a second step, new criteria of response to a single treatment are defined on morphological MRI. Contrarily to previous work, our approach takes into account not only the tumor size evolution but also the dynamic changes induced by the therapy.
KeywordsEndpoint determination Functional status Low grade glioma Malignant progression Neuro-oncology Neurosurgery Quality of life
- 2.van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583.PubMedCrossRefGoogle Scholar
- 3.van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.PubMedCrossRefGoogle Scholar
- 5.Brasil Caseiras G, Ciccarelli O, Altmann DR, Benton CE, Tozer DJ, Tofts PS, Yousry TA, Rees J, Waldman AD, Jager HR. Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. 2009;253:505–12.PubMedCrossRefGoogle Scholar
- 11.Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, Lewis RF, Harris GJ, Lev M, Schaefer PW, Buchbinder BR, Barest G, Yamada K, Ponzo J, Kwon HY, Gemmete J, Farkas J, Tievsky AL, Ziegler RB, Salhus MR, Weisskoff R. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19:551–7.PubMedGoogle Scholar